The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.
作者信息
Apolo A B, Bellmunt J, Cordes L, Gupta S, Powles T, Rosenberg J E, Van Der Heijden M S
机构信息
Center for Cancer Research, National Cancer Institute, Bethesda.
Dana Farber Cancer Institute, Boston.
出版信息
ESMO Open. 2024 Sep;9(9):103725. doi: 10.1016/j.esmoop.2024.103725. Epub 2024 Sep 5.
Abstract
摘要
相似文献
1
The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.
ESMO Open. 2024 Sep;9(9):103725. doi: 10.1016/j.esmoop.2024.103725. Epub 2024 Sep 5.
2
Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
Med. 2024 Jun 14;5(6):490-492. doi: 10.1016/j.medj.2024.04.006.
3
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Eur Urol. 2024 Sep;86(3):282-283. doi: 10.1016/j.eururo.2024.03.032. Epub 2024 Apr 16.
4
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Eur Urol. 2024 Sep;86(3):283. doi: 10.1016/j.eururo.2024.05.001. Epub 2024 May 13.
5
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Eur Urol. 2024 Sep;86(3):280-281. doi: 10.1016/j.eururo.2024.03.029. Epub 2024 Apr 9.
6
Pembrolizumab plus enfortumab vedotin in urothelial cancer.
Nat Rev Urol. 2024 Jul;21(7):387-388. doi: 10.1038/s41585-024-00858-y.
7
The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
Eur Urol Oncol. 2024 Jun;7(3):313-315. doi: 10.1016/j.euo.2024.02.010. Epub 2024 Mar 13.
8
Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
Eur Urol Focus. 2024 Mar;10(2):231-233. doi: 10.1016/j.euf.2024.05.011. Epub 2024 May 25.
9
Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
BJU Int. 2024 Jul;134(1):43-44. doi: 10.1111/bju.16245. Epub 2023 Dec 18.
10
Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma.
Eur Urol. 2024 Aug;86(2):183-184. doi: 10.1016/j.eururo.2024.03.011. Epub 2024 Mar 26.
引用本文的文献
1
Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma.
Sci Rep. 2025 Jul 18;15(1):26127. doi: 10.1038/s41598-025-09806-1.
2
Impact of concomitant medications on the oncologic efficacy of systemic therapy in patients with advanced or metastatic urothelial carcinoma: a systematic review and meta-analysis.
BMC Urol. 2025 Apr 28;25(1):107. doi: 10.1186/s12894-025-01754-2.
3
Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments.
ESMO Open. 2024 Nov;9(11):103985. doi: 10.1016/j.esmoop.2024.103985. Epub 2024 Nov 13.
Zotero 插件